glp-1 drugs for inflammation tied to lower brain inflammation, higher depression risk Can GLP-1 Drugs Boost Immunity?

doi: 10.1016/j.ejphar.2025.178088, 35

For patients who want to transition from a compounded product to an FDA-approved one, both clinicians cautioned that the process isnt always straightforward, as it may not be clear what dose a patient on a compounded product had been taking

[DOI] [PubMed] [Google Scholar] 86.Marso SP., et al

AstraZeneca PLC Boehringer Ingelheim Merck & Co., Inc

The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs